PLANNING TOOLS & RESOURCES

More information is available

Access the following Web sites and resources to learn more about influenza and pandemic influenza.

Workplace pandemic flu planning:

Business Pandemic Influenza Planning Checklist
Guidance on Preparing Workplaces for an Influenza Pandemic (PDF format)
Centers for Disease Control and Prevention (CDC) - Business Home

Prevention:

Cover Your Cough
National Institute of Allergy & Infectious Diseases (NIAID)
American Lung Association: influenza

Avian flu:

CDC - Avian Flu Information
World Health Organization - Avian Flu Information

Preparing for pandemic flu:

Department of Health and Human Services (HHS) - Pandemic Planning Update (PDF format)
HHS - HHS Pandemic Influenza Plan Fact Sheet
PandemicFlu.gov

Infection control/Surveillance:

Influenza Vaccine Information for Healthcare Workers
Flu-Related Morbidity & Mortality Weekly Reports (MMWRs)
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
World Health Organization (WHO): Flunet

Vaccines and Immunization:

The National Immunization Program (NIP)
Influenza Vaccine Information Statement
National Influenza Summit
2007 NCIRD Annual Report

Influenza:

The World Health Organization (WHO): influenza
Flu Drugs, NIAID Fact Sheet
FDA - Influenza (Flu) Antiviral Drugs and Related Information

Travelers' Health:

CDC Travelers' Health: Information on Influenza

Training & Education:

Archived Cybercasts about Influenza from the CDC's Public Health Training Network. Two July 13, 2000 cybercasts available: “Preparing for the Next Influenza Pandemic” and a “Special Session for Public Health Workers about Influenza Control.”

Disclaimer

The Pandemic Planning Web site contains links to third-party Web sites on the Internet. These links are provided as a service to individuals interested in more information. These sites are not part of this GlaxoSmithKline (GSK) Web site. The content and materials in these third-party Web sites are not produced or endorsed by GSK and may refer to uses of our products that are not recommended by GSK.

 
Important Safety Information About RELENZA

• Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
  
• RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
  
• Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions
  
• Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible
  
• If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
  
• Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups
  
• Please see complete Prescribing Information for RELENZA